Genmab A/S
GMAB
$21.78
$0.110.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.23B | 3.12B | 2.89B | 2.76B | 2.59B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.23B | 3.12B | 2.89B | 2.76B | 2.59B |
| Cost of Revenue | 157.81M | 142.81M | 112.83M | 84.14M | 59.80M |
| Gross Profit | 3.07B | 2.98B | 2.77B | 2.67B | 2.53B |
| SG&A Expenses | 560.96M | 559.96M | 516.30M | 514.43M | 506.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.15B | 2.11B | 1.94B | 1.88B | 1.76B |
| Operating Income | 1.09B | 1.01B | 943.06M | 876.89M | 829.35M |
| Income Before Tax | 1.32B | 1.32B | 954.59M | 1.09B | 1.03B |
| Income Tax Expenses | 184.77M | 192.77M | 271.38M | 287.29M | 236.00M |
| Earnings from Continuing Operations | 1.13K | 1.13K | 683.20 | 803.92 | 795.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.13B | 1.13B | 683.20M | 803.92M | 795.81M |
| EBIT | 1.09B | 1.01B | 943.06M | 876.89M | 829.35M |
| EBITDA | 1.13B | 1.06B | 980.88M | 911.39M | 861.78M |
| EPS Basic | 15.18 | 15.17 | 8.07 | 9.84 | 9.68 |
| Normalized Basic EPS | 10.98 | 10.94 | 6.92 | 8.29 | 7.50 |
| EPS Diluted | 15.06 | 15.04 | 8.01 | 9.76 | 9.59 |
| Normalized Diluted EPS | 10.89 | 10.85 | 6.87 | 8.23 | 7.43 |
| Average Basic Shares Outstanding | 631.28M | 639.94M | 641.75M | 643.56M | 644.37M |
| Average Diluted Shares Outstanding | 634.21M | 644.48M | 646.39M | 648.35M | 649.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |